Viridian Therapeutics

VRDN57

$22.50arrow_drop_up6.83%$1.44

VRDN57

$22.50

arrow_drop_up6.83%$1.44

Performance History

Key Stats
Open	$22.44
Prev. Close	$21.18
EPS	-4.25
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	20.61	22.65
52 Week Range	10.92	24.18

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.25

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Viridian Therapeutics (VRDN)

Viridian Therapeutics, Inc. (VRDN) is a biopharmaceutical company focused on the development of novel therapies for the treatment of serious diseases. The company's mission is to improve patients' lives by developing innovative and effective treatments that address unmet medical needs. With a market cap of XYZ, Viridian Therapeutics is well-positioned for future growth and success.

Viridian Therapeutics is dedicated to leveraging the power of genomics and precision medicine to develop therapies that target the underlying mechanisms of disease. By understanding the genetic and molecular basis of diseases, the company aims to design therapies that are tailored to individual patients, maximizing their chances of success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Scott D. Myers M.B.A.
Headquarters: Waltham
Employees: 86
Exchange: NASDAQ

Keep an eye on Viridian Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Viridian Therapeutics's (VRDN) price per share?

The current price per share for Viridian Therapeutics (VRDN) is $22.5. The stock has seen a price change of $1.44 recently, indicating a 6.84% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Viridian Therapeutics (VRDN)?

For Viridian Therapeutics (VRDN), the 52-week high is $24.18, which is 7.47% from the current price. The 52-week low is $10.92, the current price is 105.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Viridian Therapeutics (VRDN) a growth stock?

Viridian Therapeutics (VRDN) has shown an average price growth of 0.41% over the past three years. It has received a score of 62 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Viridian Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Viridian Therapeutics (VRDN) stock price performance year to date (YTD)?

As of the latest data, Viridian Therapeutics (VRDN) has a year-to-date price change of 0.67%. Over the past month, the stock has experienced a price change of 42.14%. Over the last three months, the change has been 84.73%. Over the past six months, the figure is 29.76%.

help

Is Viridian Therapeutics (VRDN) a profitable company?

Viridian Therapeutics (VRDN) has a net income of -$237.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -100.26K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$254.45M. Furthermore, the EBITDA is -$250.21M.

help

What is the market capitalization of Viridian Therapeutics (VRDN)?

Viridian Therapeutics (VRDN) has a market capitalization of $1.7B. The average daily trading volume is 3.96M, indicating the stock's liquidity and investor engagement.